Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  ACB | T.ACB.WS.U

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Comment by bbuddwisserr104on Jan 13, 2022 1:53pm
163 Views
Post# 34313686

RE:RE:Forbes Article: Pfizer Bets on Medical Cannabis $6.7B

RE:RE:Forbes Article: Pfizer Bets on Medical Cannabis $6.7Bi think your right on with a connection with a big pharma also as they were saying three years ago it will be multiple deals they are in deep with altria from the ceo to the connection with 22nd century an now cronos to develop cannabiniods in away no one else can legally without infrigment of the joint I.P through annadia labs which acb owns once the fda approves differnt canabiniods like hard to produce rare cannabiniods  the three of them can produce them at scale . thats the ticket  . A take over would mean a bidding war  altria and a big pharma company to buy acb 22nd century for altria to buy out since they own 40% of cronos an big pharma would need to buy all three  ithink license agreement with big pharma for the medicine part other than cbd or thc is more likely  imo 
<< Previous
Bullboard Posts
Next >>